A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis

Post-traumatic stress disorder (PTSD) is a chronic and disabling condition characterised by intrusive memories, hyperarousal, avoidance and mood and cognitive changes following exposure to traumatic events. The disorder has a substantial individual and societal burden, lifetime prevalence estimates around 3.6–3.9% worldwide, and higher rates in conflict-affected populations. A sizeable proportion of patients do not remit with standard treatments; the authors note that definitions of treatment-resistance vary but often denote failure to respond to at least two evidence-based therapies. Against this background, Illingworth and colleagues set out to evaluate whether MDMA (3,4-methylenedioxymethamphetamine) administered in a supervised clinical setting as an adjunct to psychotherapy provides benefit for treatment-resistant PTSD (TR-PTSD). Earlier phase 1 and phase 2 work suggested MDMA can facilitate psychotherapy through pro-social, anxiolytic and fear-reducing effects, but trials are small and blinding is challenging. This systematic review and meta-analysis therefore aimed to identify double-blind randomised trials comparing MDMA-assisted psychotherapy to psychotherapy plus placebo and to quantify effects on clinician-rated PTSD severity (CAPS-IV), depressive symptoms (BDI) and adverse events, including session and 7-day follow-up events.

The review was prospectively registered on PROSPERO (CRD42019109132) and followed PRISMA guidance. The investigators searched PUBMED, PsycINFO, EMBASE and MEDLINE from September 2018 to February 2020 for double-blind randomised controlled trials of MDMA-assisted psychotherapy in TR-PTSD (search terms included MDMA, 3,4-methylenedioxymethamphetamine, psychotherapy, PTSD). Two reviewers independently screened titles/abstracts, assessed full texts for eligibility and extracted trial characteristics. Discrepancies were resolved by discussion, contact with study authors, or a third reviewer. Eligible studies required a PTSD diagnosis and randomised comparison between MDMA plus psychotherapy and placebo plus psychotherapy; active placebo was defined as a lower MDMA dose and inactive placebo as a non‑psychoactive substance. Trials conducted in inpatient or outpatient settings were eligible. Primary outcomes pre-specified were change in Clinician Administered PTSD Scale (CAPS-IV) at more than 3 weeks after blinded sessions and Beck Depression Inventory (BDI). Secondary outcomes included psychological (anxiety, low mood, insomnia) and physical adverse events (jaw clenching, insomnia, nausea, headache, anorexia) during sessions and at 7-day follow-up. Risk of bias for each trial was assessed using the Cochrane Risk of Bias tool. Review Manager 5.3 was used for analysis. Given heterogeneity, a random-effects inverse-variance model was applied for primary outcomes; fixed-effects (Mantel–Haenszel) models were used for many secondary outcomes. When event rates were very low, Peto odds ratios were employed. The authors contacted original trial investigators to clarify or obtain missing data when necessary.

The search yielded 688 references; after deduplication and screening, six RCTs reporting 109 participants initially met criteria but two were excluded (one lacked appropriate follow-up, one duplicated participant data), leaving four randomised trials totalling 85 participants for the primary analyses. Individual trial sizes ranged from 12 to 28 participants. All included trials reported the primary outcome of CAPS-IV change after at least 3 weeks. For the primary PTSD outcome, intervention groups receiving MDMA plus psychotherapy showed significant reductions in CAPS-IV scores at certain doses. Compared with active placebo, the 75 mg and 125 mg MDMA groups had statistically significant decreases in CAPS-IV; the 100 mg group did not reach statistical significance (MD = -12.90; 95% CI -36.09 to +10.29; p = 0.28). When compared to inactive placebo, the 125 mg MDMA plus psychotherapy group also showed a statistically significant reduction in CAPS-IV (reported MD -33.20; the extracted text reports the 95% confidence interval as -0.53, -25.87 and p < 0.00001, but the ordering of the interval in the extraction is unclear). Regarding depressive symptoms, only the 75 mg MDMA plus psychotherapy arm showed a significant improvement in Beck Depression Inventory scores (MD -10.80; p = 0.02). The extracted Results text did not clearly report the 95% CI for this estimate, although the abstract presents it as -20.39 to -1.21. No significant BDI differences were reported for the 100 mg and 125 mg comparisons. Secondary outcomes demonstrated increased rates of several physical adverse events in MDMA arms. Jaw clenching occurred significantly more often at several dose levels: 75 mg (Peto OR 13.46; 95% CI 1.44, 125.80), 125 mg per patient (Peto OR 7.34; 95% CI 1.98, 27.71), 125 mg per session (Peto OR 4.08; 95% CI 1.04, 15.99) and 150 mg (RR 8.67; 95% CI 1.21, 61.91); the 100 mg comparison did not reach significance (RR 1.67; 95% CI 0.47, 5.96). Nausea during sessions and lack of appetite within 7 days were more frequent with 125 mg MDMA compared with inactive placebo (reported RR 4.00; 95% CI 1.03, 15.53; other CI reporting in the extraction is incomplete). The authors summarised session-level frequencies across trials: nausea occurred in 58% of sessions, low mood in 17% of sessions, jaw clenching in 30% of sessions and lack of appetite within 7 days in 25% of sessions; jaw clenching was particularly common at the highest reported dose (67% of 150 mg sessions). Four serious adverse events were reported across studies, including episodes of suicidal ideation and one hospital admission related to suicidal thoughts. The authors also noted compromised blinding in included trials, citing evidence (from Mithoefer et al.) that most participants and therapists could correctly guess treatment assignment after higher doses.

Illingworth and colleagues interpret their findings as indicating that MDMA-assisted psychotherapy is associated with clinically meaningful reductions in clinician-rated PTSD severity (CAPS-IV) in treatment-resistant PTSD, at doses of 75 mg and 125 mg when compared with active placebo and at 125 mg versus inactive placebo; the 100 mg comparison did not reach significance. The authors emphasise that depressive symptoms, as measured by BDI, showed limited improvement overall, with a significant change observed only at the 75 mg dose. The discussion situates these results within earlier phase 2 work showing feasibility and promising signals of efficacy, and notes the biological and psychological rationale for MDMA as a psychotherapy adjunct (reduced fear, increased trust and openness). Safety was described as largely favourable for neurocognitive and physical risk at therapeutic doses under clinical supervision, but notable transient somatic adverse effects and some instances of increased suicidal ideation were observed. The reviewers highlight that some adverse events (for example jaw clenching) showed a dose–response relationship, arguing against adopting higher doses without clear additional benefit. Key limitations acknowledged by the authors include the small number of trials and small sample sizes, inconsistent reporting of secondary outcomes across studies, and likely suboptimal blinding because doses produced perceptible psychoactive effects. These factors increase uncertainty and limit generalisability. The authors recommend the development of a core outcome set for PTSD trials to harmonise reporting (for example standardising measures such as BDI/PHQ-9/GAD-7 and CAPS-IV measurement intervals) and to capture adverse events up to 12 months. Finally, the paper notes that ongoing Phase 3 trials will be important to establish efficacy and safety more definitively, that subgroup analyses may identify populations most likely to benefit, and that the intervention should be seen as a combined drug-plus-psychotherapy treatment requiring skilled therapeutic management rather than as a pharmacological or psychotherapeutic intervention in isolation.

The authors conclude that MDMA-assisted psychotherapy is associated with significant reductions in CAPS-IV scores in subjects with treatment-resistant PTSD but has little consistent effect on Beck Depression Inventory scores. They describe a potential therapeutic benefit with minimal neurocognitive risk when administered in a controlled clinical setting, while emphasising that findings must be interpreted cautiously given small sample sizes and limited trial numbers. Larger-scale studies are required to clarify efficacy, safety and optimal dosing before clinical implementation can be recommended.